Larvol Delta - Arthrosi-Announces-First-Patient-Dosed-in-Replicate-Pivotal-Phase-3-REDUCE-1-Trial-of-Lead-Compound-AR882

AR882 - Arthrosi

https://www.prnewswire.com/news-releases/arthrosi-announces-first-patient-dosed-in-replicate-pivotal-phase-3-reduce-1-trial-of-lead-compound-ar882-302401240.html

Mar 17, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next